Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The company plans to expand its portfolio in regulated markets aggressively
Subscribe To Our Newsletter & Stay Updated
